News

The social value of decreasing health risks to people of different age, health status, and income depends on the evaluation framework employed in an analysis. These values can be evaluated using cost-effectiveness

After two remote years, the Decision Science summer courses return to being fully in-person this summer. In both 2020 and 2021 the courses were taught via synchronous ZOOM sessions

Conventional benefit-cost analysis is well-established and widely used globally to assess policy options that profoundly affect public health. The normative assumptions that underlie the

CHDS faculty Stephen Resch and Research Staff Joseph Corlis produced “A Roadmap for Implementing Change in Costing Capacity and Practices” as part of a project supported by the

Fangli Geng, Ph.D. candidate at CHDS, collaborated with researchers from the Chinese Academy of Medical Sciences & Peking Union Medical College to develop

COVID-19 vaccination is substantially more cost-effective than lockdowns, according to research conducted by CHDS faculty affiliate Joseph Pliskin and Ronen Arbel. Early in the COVID-19

CHDS faculty Ankur Pandya received the 2022 Roger L. Nichols Award for Excellence in Teaching at the Harvard Chan School’s Commencement Ceremony. The award is selected through a review of

CHDS faculty Ankur Pandya outlined how economic evaluation methods could be used to improve the process of making difficult policy choices around COVID-19 in a recently co-authored 

Steven Pearson spoke about the role of the Institute for Clinical and Economic Review (ICER) in encouraging the consideration of cost-effectiveness in US drug policy in a recent CHDS seminar.

The EPIC team at CHDS, led by CHDS faculty Stephen Resch, performed a systematic review of literature to describe research on the costs and cost-effectiveness of integrating